Osaka Medical and Pharmaceutical University, Fukui Tateami and Teijin Achieve Primary Endpoint in Cardiovascular Patch Clinical Trial
Osaka Medical and Pharmaceutical University, Fukui Tateami Co., Ltd. and Teijin Limited announced today that they have achieved the primary efficacy endpoint in an ongoing clinical trial of the OFT-G1…